BioSpace News Archive

Galmed Pharmaceuticals Ltd. provides today a business update and reports financial results for the three and six months ended June 30, 2022.

Biostage, Inc.today announced that it will release Q2 2022 financial results on August 4, 2022 and host a conference call and webcast on August 5, 2022 at 9:00 AM ET to discuss financial results and business updates for the second-quarter 2022.

Thorne HealthTech, Inc. (“Thorne HealthTech” or “Thorne”) (NASDAQ: THRN), a leader in developing innovative solutions for a personalized approach to health and wellness, today announced a two-year continuation of the collaboration with AstraZeneca, a leading biopharmaceuticals company.

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) (“Acurx” or the “Company”), a clinical stage biopharmaceutical company developing a new class of antibiotics for difficult-to-treat bacterial infections, announced today that the Company will release its 2022 second quarter financial results on Tuesday, August 16, 2022.

While the opioid overdose and death epidemic continues to worsen across the United States, medications such as methadone, buprenorphine and extended-release naltrexone are proven to reduce opioid overdoses by more than 50 percent.

ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the second quarter of 2022 on Monday, August 15, 2022 after the close of trading on the U.S. financial markets.

Lineage Cell Therapeutics, Inc. today announced that it will report its second quarter 2022 financial and operating results on Thursday, August 11, 2022, following the close of the U.S. financial markets.

Apnimed announced today the company will be participating in the upcoming 42nd Annual Canaccord Genuity Global Growth Conference in Boston, Massachusetts taking place on August 8-11, 2022.

Endologix LLC , a privately held global medical device company dedicated to improving patients’ lives with innovative interventional treatments for vascular disease, announced that is has received CE Mark Certification under the new EU Medical Devices Regulation [EU-MDR [(Regulation (EU) 2017/745)] for its AFX2 Endovascular AAA System.

Astria Therapeutics, Inc. today announced initiation of a Phase 1a clinical trial of STAR-0215 in healthy subjects.